Transformative versus conservative automotive innovation styles: contrasting the electric vehicle manufacturing strategies for the BMW i3 and Fiat 500e

The automotive industry is a critically important stakeholder influencing the sustainability of passenger transport. How traditional car manufacturers respond to carbon reduction and vehicle targets, alongside other selection pressures, can greatly influence the availability and affordability of new innovations such as electric vehicles. In this paper, we explore the automotive innovation styles surrounding two electric vehicles: the BMW i3, and the Fiat 500e. To do so, we tie together ideas from technological innovation systems and corporate product innovation style. Our results illustrate a case of a “compliance car,” the Fiat 500e, vs. the first mass production EV by a major German car manufacturer, the BMW i3. BMW adheres to a transformative change-shaping innovation style that attempts to promote in-house learning that can create value. Fiat adheres to a conservative sustaining innovation style that attempts to outsource innovation, promotes limited learning, and focuses on maintaining value. Both styles interestingly result in converging product development patterns over time

Why are mineralocorticoid receptor antagonists cardioprotective?

Two clinical trials, the Randomized ALdosterone Evaluation Study (RALES) and the EPlerenone HEart failure and SUrvival Study (EPHESUS), have recently shown that mineralocorticoid receptor (MR) antagonists reduce mortality in patients with heart failure on top of ACE inhibition. This effect could not be attributed solely to blockade of the renal MR-mediated effects on blood pressure, and it has therefore been proposed that aldosterone, the endogenous MR agonist, also acts extrarenally, in particular in the heart. Indeed, MR are present in cardiac tissue, and possibly aldosterone synthesis occurs in the heart. This review critically addresses the following questions: (1) is aldosterone synthesized at cardiac tissue sites, (2) what agonist stimulates cardiac MR normally, and (3) what effects are mediated by aldosterone/MR in the heart that could explain the beneficial effects of MR blockade in heart failure? Conclusions are that most, if not all, of cardiac aldosterone originates in the circulation (i.e., is of adrenal origin), and that glucocorticoids, in addition to aldosterone, may serve as the endogenous agonist of cardiac MR. MR-mediated effects in the heart include effects on endothelial function, cardiac fibrosis and hypertrophy, oxidative stress, cardiac inotropy, coronary flow, and arrhythmias. Some of these effects occur via or in synergy with angiotensin II, and involve a non-MR-mediated mechanism. This raises the possibility that aldosterone synthase inhibitors might exert beneficial effects on top of MR blockade

Lack of rapid aldosterone effects on forearm resistance vasculature in health

Systemic infusions of aldosterone cause an acute increase in systemic vascular resistance (SVR) in healthy subjects. It is not clear whether this is due to a direct effect on the vasculature or the result of increased sympathetic tone. We investigated the short-term effects of locally infused aldosterone on the forearm resistance bed